Study of an artificial human tissue medicament for patients with severe corneal ulcers that not respond to conventional therapies.

You likely can't join if

• Patients included in the study cannot meet any of the following exclusion criteria: 1. Corneal pathology that responds well to standard medical treatment within less than 3 weeks 2. Active ocular infection 3. Endothelial decompensation or bullous keratopathy 4. Visual acuity below light perception 5. Positive serology for HBV, HCV, HIV or coexistence of any other pathology that, at the investigator's discretion, prevents the patient from continuing in the trial. In the case of HIV, it is understood that a positive serology implies a positive value for the anti-HIV antibody. In the case of HCV, a positive serology is defined as a positive anti-HCV antibody value. Finally, in the case of HBV, a positive serology is interpreted as a positive HBV antigen value or a positive viral load value (HBV-NAT). Inclusion of the subject will not be rejected if a positive anti-HBVc antibody is present and anti-HBVs immunization levels are sufficiently high to ensure adequate protection of the patient (anti-HBVs>100 IU/L). 6. Pregnant or breastfeeding women. 7. History of active malignancy within the last 5 years 8. Patients who have participated in the last 3 months prior to the inclusion of the study in a clinical trial. This period will be extended for clinical trials in advanced therapies, excluding from this trial those patients who have participated in the last 5 years in a clinical trial of advanced therapies.